Korro Bio is trading 6.2% down today at $13.41 amid ongoing post-trial volatility, with no new company-specific headlines emerging.
- Shares remain pressured in the wake of prior negative developments, including the failure of lead candidate KRRO-110 and a paused RNA partnership with Novo Nordisk.
- Today’s move appears to be normal volatility in a thinly traded, speculative biotech rather than a reaction to new disclosures.